RIPK2 was significantly upregulated in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), ESCA (esophageal carcinoma), COAD (colon adenocarcinoma), CHOL (cholangiocarcinoma), HNSC (head and neck cancer), STAD (stomach adenocarcinoma), READ (rectum adenocarcinoma), KIRC (kidney renal clear cell carcinoma), LUAD (lung adenocarcinoma), UCEC (uterine corpus endometrial carcinoma), THCA (thyroid carcinoma), LIHC (liver hepatocellular carcinoma), and PRAD (prostate adenocarcinoma) compared to that in their respective normal tissues. Here, RIPK2 is linked to rectum adenocarcinoma.